Why the study?
How should heparin be administered for the treatment of venous thromboembolic disease?
How should heparin be administered for the treatment of venous thromboembolic disease?
This paper provides historical guidelines for the administration of heparin in venous thromboembolic disease, highlighting the need for standardized dosing.
Answers are grounded in this paper and cite their sources.
Standardized adequate heparin dosing is required for effective VTE treatment; extends observational evidence into clinical guidelines.
Although heparin has been used in the treatment of venous thromboembolism for more than 25 years, confusion remains as to its most effective administration. Dosage, route, and duration of therapy vary considerably from one institution to another. The whole-blood clotting time to control therapy is advocated by many and abjured by others. This general lack of standardization seems largely responsible for current disagreement regarding the likelihood of so-called "anticoagulant failure" and the incidence of significant hemorrhage. As a consequence, the degree of enthusiasm of alternate methods of therapy differs widely. The paucity of well-controlled clinical trials unfortunately precludes many final answers. Nevertheless, it is possible to formulate certain guidelines for the use of heparin in venous thromboembolic disorders, based on clinical and experimental observations. There is reason to believe that dose requirements are often not given sufficient consideration. Much of the clinical value of this drug may be lost through
No takes yet. Share an insight, caveat, or question.
Victor Gurewich (1967) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: